Member Info for Nolupus

Everyone to their own trades and convictions. .

You may be right or wrong but whatever, it's your Money ..

Only Time will tell

'New evidence shows that P140 restores the tolerance systems by enabling tolerogenic antigen presenting cells (like dendritic cells) to function properly. As malfunction of the tolerance systems seems to be the root cause of most if not all autoimmune diseases, it explains why P140 is so broadly efficient across most autoimmune indications in animal models. P140 is the only non-immunosuppressive molecule in the industry in clinical development for the treatment of SLE.'

One could imagine that some Big pharma

Would be interested in testing some other auto-immune diseases ....

I am also intrigued by this ' NEW' evidence , and where it came from ? Hopefully WE may see some publication in a medical journal ..

You are correct in stating that the warrants and their dikutory effect are a major drawback to shareholders ...

Imm has failed ( so far ) to sign a deal WITH a large upfront payment ...will THIS change shortly ? Who knows ..

Flash212,

You could of course be right in your assumptions but IMM have possible other options going forward ( instead of Landstead)

In Reading between the lines and analysing the Uturns and 'delays' in the Last few MONTHS, one maybe inclined to believe that a 'third party' has given their imput ... ( All conjecture, of course )

It would not surprise me to see another Rns in the Next few weeks which could shone a different light on things ...

Let's wait and see..

Trek,

The Voucher IS an incentive to do research on orphan afflictions where the patient population IS small and therefore not attractive to large pharma..The voucher IS only granted once thé product gains FDA approval and the voucher IS usually then sold off to Big pharma ...

Anyway my point IS that WE are a long way off before getting our hands on one of these vouchers so let's not focus too much on them for the moment ...

There is a Big différence between Fast track status and getting a voucher ..

The fast track status means you get a priority review which means you Can Come before the review board upto 6 MONTHS before you could have ....

Getting a voucher worth UPto nearly $ 109 million IS a différent kettle of fish ..

Your product has to cross thé Line before you get eligible ...otherwise everyone could benefit by getting their clinical costs paid ... No way José...

Mystic Mike,

WE could/should get the first patient dosed in H1 2024 imo

But when will the Last patient get their first dosing IS the BIG question and AT THIS stage it's impossible to Say ..

We are awaiting the trial protocol to bé published to see how many patients are required and what IS the 'estimated' readout date for the trial ...

One cannot make UP the Rules to suit ourselves ...

The Voucher Comes After and not before ..

But please dyor..

FORGET about the VOUCHER , UNTIL they get FDA approval ...WE are Years away ...

Cauldstream7,

I am sorry to Say that you are incorrect

The CRO has been chosen BUT no patients Can be recruited UNTIL the clinical trial sites have been chosen and the TRIAL protocol has been annonced and posted on the Clinical trial website ..

AGAIN

Patient recrutement does not Take weeks but many many MONTHS and more depending on the number of patients to be enrolled ...

Clinical trials Take Time and cannot bé RUSHED despite shareholders frustrations ..

Thanks wildbunch,

You only listening to yourself , anyway :-)

dallo,

art may not be the sole pilot in the ****pit for much longer , me thinks but wtfdik ...

the airplane has a limited airspace , let's see when the smoke screen is lifted 😜

Pokerchips and Dallo,

As longtimers, you should know that any Rns has to bé dissected and reread many Times so as to see what IS being Said ( and NOT Said )

My contrarian viewpoints are well known to you Both so all i will Say is THIS update stinks ...

Stinks of what ?

Perfume or septic tanks ?

My mind says one , and not the other 😜

Very intriguing RNS With lots of things to digest ..

Timescales will be important to check as they are doing a dose escalation P3 study .. but am awaiting the trial protocol to see what IS the difference between what was initially annonced and NOW ..

Leisterinvestor,

One cannot talk about patient recrutement UNTIL the CRO has been appointed AND the clinical trial sites have been chosen ...

After 'investing' £2.25 million in Incanthera, Imm has informed us that Incanthera has raised a further £1 million, yet they don't mention if IMM participated .... Strange ?

THIS IS a bottom drawer stock imo and therefore just Take a peek in every now AGAIN ..

But everyone to their own views

Probably flatulence...

Wildbunch,

To be Frank, i cannot class IMM or many other biotechs as 'investments' ... We do of course put our Money in but i prefer to call them 'punts' rather than investments as they are very High risk / volatile stocks .

Anyway, i do agree that the risk/reward ratio seems very attractive at this Time ..and some People may be awaiting further confirmation on the Avion commitment before 'investing' in IMM

Que sera sera

Wildbunch,

IS IT irrelevant to try to answer a question asked by Cauldstream7 ?

As we Both know , Avion will Never give $25 million in one go to IMM to fund the trial so please don't try to be 'too' smart ...